Oncotelic has two pharmacological agents in clinical trials to manage Covid-19, the disease caused by the SARS-CoV-2 virus. OT-101 and ARTIVeda both work by inhibiting TGF-β to neutralize the SARS-CoV-2 virus.
Upon assessing the broad impact of the SARS-CoV-2 virus and associated COVID-19 complications, the company tested OT-101 and Artemisinin, both of which showed potent activity in the lab and promising data for treating the virus infection and associated complications based on their mechanism of action.
TGF-β inhibitor to address the COVID-19 pandemic in India.
OT-101 has a similar mechanism of action as ARTIVeda, and is currently in phase 2 testing.
AGOURA HILLS, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”) today announced the approval of a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for the development of OT-101 under a project named OT-101 – a transforming growth factor-beta (TGF-β) therapeutics against long-term effects of respiratory distress post COVID-19.
The scope of the project supported by BARDA includes collecting the long-term clinical data on COVID-19 patients in Peru and Argentina where C001-2020-01 trial was conducted and to demonstrate potential effectiveness of OT-101 against the long-term effects of respiratory distress post COVID-19. The data will be used to design the next clinical trial aiming at demonstrating effectiveness of OT-101 against COVID-19 and long-term COVID-19.
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50122C00066..